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Endogenously radioiodinated thyroglobulin (tg) and thyroxine (T4), in the circulation following, thera- 
peutic doses of radioiodine were studied in five patients with differentiated thyroid carcinoma. Radio- 
active serum was fractionated on a Sephadex G-200 and the various radioactive peaks thus obtained 
were analyzed for their biochemical and immunologic characteristics using precipitation with trichlo- 
roacetic acid (TCA) and antithyroglobulin antibody extraction with acidified n-butanol and electropho- 
resis on agar gel. The disappearance rates of endogenously labelled tg and T4 were 3.12 -t 0.396 days 
and 10.14 f 1.81 days, respectively. 
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T IS AN ESTABLISHED FACT that iodoproteins in the I circulation, including iodinated tg, are released after 
radioiodine treatment in patients with differentiated 
thyroid carcinoma.'-4 The various proteins such as tg, 
thyroxine binding globulin TBG, iodoalbumin, and/or 
an unknown protein X, whose biologic function is as 
yet poorly understood, have been studied in these sera; 
biophysical and biochemical methods, such as electro- 
phoresis, salting out, and immunoreactivity, have been 
used. However, the physiologic significance and the 
amount of functioning mass required to produce certain 
definite amounts of tg remain unclear. Moreover, the 
biologic half-life of tg in  the circulation appears to be 
at  ~ a r i a n c e . ~ . ~  Lo Gerfo et al. have shown that the post- 
operative immunoreactive tg disappears from the cir- 
culation, with an average half-life of 14 hours in pa- 
tients with thyroid carcinoma and no metastases.6 In 
contrast, studies of patients with disease other than thy- 
roid carcinoma have shown serum tg as a multicom- 
ponent system with a varying biologic half-life.5 
In both the above-mentioned studies, the biologic 
half-life of tg in circulation was estimated using ra- 
dioimmunoassay (RIA) after thyroidectomy. It was 
therefore of interest to study the disappearance rate of 
endogenously labelled tg and T4 in thyroid carcinoma 
patients who had undergone thyroidectomy but had 
functioning metastatic mass and had received thera- 
peutic doses of radioiodine. 
Materials and Methods 
Study Subjects 
Five patients with thyroid carcinoma who had under- 
gone thyroidectomy but had functioning metastases, as 
evidenced by scintiscan, were studied. The histologic 
diagnosis, metastatic lesion, and previous I3'I therapy 
of these patients are shown in Table 1. 
Blood specimens were drawn at  different time inter- 
vals after radioiodine therapy for a period of 10-22 
days, depending on the amount of radioactivity in cir- 
culation. 
Fractionation of Patient's Serum on Sephadex 
G-200 Column 
One-half milliliter of serum was chromatographed 
on a 100 X 2.5 cm Sephadex G-200 column (Pharmacia, 
Uppsala, Sweden) using phosphate-buffered saline 
(PBS) sodium phosphate 0.0035 mol/liter, NaCl 0.15 
mol/liter with NaN, 0.2 g/liter as an eluent. An LKB 
7000 Ultrorac fraction collector was used to collect 1- 
ml fractions and each milliliter was counted for radio- 
activity with gamma ray spectrometer. 
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Characterization of Radioactive Peaks 
The three radioactive peaks (A, B, and C) obtained 
by chromatography (Fig. 1) were subjected to precip- 
itation with trichloroacetic acid (TCA) and antithy- 
roglobulin antibody, extraction with acidified n-butanol 
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TAeLt I .  Histologic Diagnosis and Therapeutic Data for Thyroid Cancer Patients 
Dose of I3'l Amount of previous '"I 
Patient Histologic diagnosis Metastases in mCi therapy 
N Follicular carcinoma Lymph node 100 I (90 mCi I3'I)  
M Follicular carcinoma Skull 100 
K Follicular and papillary carcinoma Lymph node 230 2 ( I  10 + 250 mCi '"I)  
S Follicular carcinoma Sternum I40 
P Follicular carcinoma Sternum I00 - 
- 
- 
and electrophoresis on agar gel for identification of io- 
dine linkage. 
Percent Radioiodinated rg in the Sample 
in the sample was calculated as: 
Percent activity with peak A 
The percent of radioiodinated tg (peak A)  present 
Radioactive counts under peak A 
Total counts in  all three peaks 
x 100. - 
Biologic Half-LVe of Radioiodinated tg 
One milliliter of serum of all the samples collected 
on various days from the same patient after radioiodine 
therapy were counted on the same day to take care of 
the physical decay correction. Absolute radioactive 
counts associated with tg in each sample were then cal- 
culated by multiplying the total counts/ml of serum 
with percentage radioactivity of thyroglobulin and di- 
viding by 100. The counts thus obtained were plotted 
against the day on which the sample was collected. The 
slope of the declining phase of radioactivity was taken 
for the determination of biologic half-life. 
Biologic Half-Life of Radioactive Thyroxine (T4) 
Acidified n-butanol was used to extract thyroxine 
from the serum of patients treated with radioiodine; 
0.25 ml of serum was diluted to 1 ml with normal saline 
and counted for radioactivity. This was then extracted 
three times successively with 3 ml of acidified n-butanol. 
The organic phase was pooled, made to a volume, 
washed with alkali (5% Na2C03 in 4N NaOH) and 1 
ml of alkali washed organic phase was counted for ra- 
dioactivity (mainly T, and a small amount of T3). Per- 
cent radioactivity with thyroxine was then calculated 
from the original serum counts (it is assumed that the 
contribution of T, to BE1 is negligible in comparison 
with T,, as the amount of T4 in circulation is much 
higher than T3). Absolute counts associated with T, in  
the serum were derived, as with the case of tg, and the 
values obtained were plotted as a function of time for 
calculation of biologic half-life. 
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FIG. 1. Chromatographic separation of radio- 
active serum on Sephadex G-200. The void vol- 
ume peak (Peak A )  is shown by shaded area. 
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Results 
Characterization of Radioactive Peaks Obtained by 
Molecular Sieve Chromatography 
The first radioactive peak obtained on chromatog- 
raphy (peak A )  was precipitable with TCA and also by 
anti-tg antibody, indicating the protein nature and the 
reactivity of tg. Radioiodine with this protein could not 
be extracted with butanol (NBEI), indicating that the 
binding of radioiodine is covalent in nature. Electro- 
phoretic mobility of this protein in agar gel was between 
the crI-a2 region. 
Peak B radioactivity also was precipitable with TCA. 
About 60-80% of the radioactivity in this peak could 
be extracted with acidified n-butanol (BEI), indicating 
the presence of thyroid hormones and that the remain- 
ing non-extractable radioactivity (NBEI) could be io- 
doalbumin or an unidentified protein X. 
The last radioactive peak (peak C )  was mainly com- 
posed of free iodide. 
Biologic HalJ1Live.r of Radioiodinated tg and 
Radioactive T, 
Radioiodinated tg in the circulation initially rose in  
all patients studied, reached a maximum value (the 
period varied from patient to patient), and then slowly 
disappeared as a function of time. The disappearance 
curve of radioiodinated tg in the circulation of one of 
the patients who received 90 mCi of radioiodine is de- 
picted in Figure 2. The radioiodinated tg reached a 
maximum value on the eighth day after radioiodine 
therapy, and then disappeared; it had a biologic half- 
life of three days. The day on which the maximum 
amount of tg appeared in circulation varied between 2- 
8 days in the five patients studied. Although the at- 
tainment of maximum activity varied, the disappear- 
ance rate of circulating radioiodinated tg was fairly 
constant (2.8-3.8 days) in  the five patients studied, ir- 
respective of amount of tg in the circulation (Table 2). 
The variation in the level of radioactive T, in the 
same patient (P )  is depicted in Figure 2 (dotted line). 
On the eighth day, the release of radioactive T4 also 
reached a maximum value similar to that of radioio- 
dinated tg. I n  all five cases studied, radioactive T4 rose 
to a maximum along with radioiodinated tg, and then 
declined. The disappearance rate of radioiodinated T4, 
however, varied between 7.2-12.2 days with a mean of 
10.14 * 1.81 days (Table 2). 
Discussion 
Quantitation of serum tg in patients with differen- 
tiated thyroid carcinoma is now considered a true bio- 
TABLE 2 .  Biologic Half-Life of Radioiodinated tg and Radioactive 
T, of Thyroid Carcinoma Patients Studied - 
Biologic half-life 
Radioiodinated Radioactive 
S No. tg T4 
I 3.8 12.2 
2 2.R 10.5 
3 3.0 10.5 
4 3. I 7.2 
5 2.9 10.3 
Mcan 3. I2 t 0.396 10.14 T 1.81 
chemical marker for the presence of metastases or re- 
currence of disease after treatment.'. I '  However, very 
little is known about its biologic half-life, metabolic 
fate, and physiologic significance in circulation. The 
data presented in  this paper indicate that the biologic 
half-life of endogenously labelled tg is between 2.8-3.8 
days with a mean of 3.1 2 0.39 days, which is in agree- 
ment with that reported by Ulla-feldt et al. using RIA 
p roced~re .~  They have shown the presence of different 
I300 
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FIG. 2 .  A typical graph showing the biologic half-life of radioio- 
dinated tg and radioactive T,. The experimental procedure is described 
in the text. 
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molecular weight tg in the circulation, of which a larger 
component-1 9 S tg-disappeared with a biologic half- 
life of 3.7 & 0.9 days and smaller molecules disappeared 
with a biologic half-life of 4.3 k 2.1 hours. In our study, 
we followed the first radioactive peak, eluted near the 
void volume, which is believed to be predominantly the 
19 S type. Moreover, i t  is assumed that during the de- 
clining phase of tg level, radioiodination of newly syn- 
thesized tg, if any, would be negligible for these reasons: 
(1) the amount of radioiodine in  serum from the initial 
administered dose would be negligible by 72 hours and 
thus its contribution in radioiodination of tg is expected 
to be insignificant; (2) the free radioiodine derived from 
metabolism of iodoaminoacids and iodoproteins also 
would not make a significant contribution in radioio- 
dination of newly synthesized tg. 
Lo Gerfo et al., i n  contrast, have reported that the 
biologic half-life of tg in patients with thyroid carci- 
noma without metastases is 14 hours.6 One of the pos- 
sibilities could be the lower molecular weight (s)  of tg 
released into circulation after thyroidectomy, which 
might bring down the biologic half-life of total tg in  the 
circulation as the biologic half-life of lower molecular 
weight tg is as low as 4.3 f 2.1 hours.5 The other pos- 
sibility could be the lower sialic acid content of tg in  
patients with thyroid carcinoma. It has been shown that 
the sialic acid content of tg from a rat thyroid cancer 
is low and also that asialo glycoproteins are removed 
at a much faster rate than that of their native forms."," 
Also, in our experience with animal studies, native tg 
disappeared with a biologic half-life of 4 hours, whereas 
the desialylated tg disappeared with a biologic half-life 
of 5 minutes when injected intravenously into a rat 
(unpublished data). The sialic acid content does not 
appear to be the cause of discrepancy, as our patients 
also had carcinoma of the thyroid with metastases. 
Thus, the discrepancy in biologic half-life of tg may be 
because of the presence of tg of various molecular 
weights in the circulation after thyroidectomy and the 
heteroassay system of RIA or hitherto unknown factors. 
The circulating radioiodinated tg reached a maxi- 
mum level between 2-8 days in different patients stud- 
ied. This could depend on the amount of radiation dose 
delivered to the tumor mass, type of tumor, histology, 
and/or some unknown factors present. The disappear- 
ance of radioiodinated tg does not necessarily mean 
absence of functioning tumor mass. Serial determina- 
tion of serum tg by RIA is therefore required to monitor 
the efficacy of radioiodine treatment in these patients. 
Both radioiodinated tg and radioactive T, showed a 
parallel rise-they reached a peak at  the same time but 
disappeared with different biologic half-lives. The bio- 
logic half-life of T, ( 10.14 k 1.8 1 days) obtained in this 
study appears to be slightly but significantly higher than 
that reported i n  the literature.', Moreover, the time 
period of increase, attainment of peak, and decline 
thereafter coincided with that of radioiodinated tg (Fig. 
2). If thyroid is the only source of T4 production, then 
T, production would have declined at a normal biologic 
half-life of 6-8 days after a maximum release is ob- 
tained. The increased biologic half-life of T, in these 
patients could be due to extra thyroidal synthesis, pos- 
sibly from tg circulation during its metabolism. These 
data support the hypothesis formulated by Daniel et al. 
that because of the intrinsic thyroxine (T, and T,) con- 
tent of tg, metabolic effects may occur in the peripheral 
tissue." Brown and Jackson also have established by 
injection of radioactively labelled tg in rats and mon- 
keys that T, appears in plasma.'6 
Thus, it is possible that a certain amount of T4 pro- 
duced during tg metabolism would add to the existing 
pool of T4 and show an apparent increase in  the biologic 
half-life. 
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